title: Unfractionated Heparin during the Interruption of Antiplatelet Therapy for Non-cardiac Surgery after Drug-eluting Stent Implantation.
abstract: OBJECTIVE
  Heparin is not recommended to be administered during the interruption of antiplatelet therapy for non-cardiac surgery. However, there are insufficient data to determine the value. The purpose of the present study was to evaluate the clinical results of the administration of unfractionated heparin during the interruption of antiplatelet therapy in non-cardiac surgery patients who had previously undergone drug-eluting stent (DES) implantation.
  
  
  METHODS
  We retrospectively identified 210 elective non-cardiac surgical procedures that were performed with the administration of unfractionated heparin during interruption of all antiplatelet therapies in patients who had previously undergone DES implantation. Heparin was administered during the perioperative period in accordance with the local practice guideline at out institution. We examined the clinical outcomes within 30 days of surgery.
  
  
  RESULTS
  The mean number of implanted DESs was 2.1±1.3. No major adverse cardiac events (including cardiac death, definite stent thrombosis, and non-fatal myocardial infarction) occurred in any of the 210 cases within 30 days of surgery. Four of the 210 cases (1.9%) required reoperation for bleeding within 30 days of surgery.
  
  
  CONCLUSIONS
  Our data showed the potential for the perioperative management with unfractionated heparin administration in Japanese patients who had previously undergone DES implantation who required non-cardiac surgery with the interruption of all antiplatelet therapies.
authors.affiliation: Department of Cardiology, Nagoya University Graduate School of Medicine, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Tanaka
authors.forename: Hideki
authors.initials: H
authors.lastname: Ishii
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Tatami
authors.forename: Yohei
authors.initials: Y
authors.lastname: Shibata
authors.forename: Naohiro
authors.initials: N
authors.lastname: Osugi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Ota
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kawamura
authors.forename: Susumu
authors.initials: S
authors.lastname: Suzuki
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Nagao
authors.forename: Tadashi
authors.initials: T
authors.lastname: Matsushita
authors.forename: Toyoaki
authors.initials: T
authors.lastname: Murohara
mesh_terms: D000368:Aged; D000075202:Contraindications; D003328:Coronary Thrombosis / Q000517:prevention & control*; D004334:Drug Administration Schedule; D054855:Drug-Eluting Stents; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D019616:Thoracic Surgical Procedures / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D006493:Heparin